January 2026 Research Update

This month added small but practical signals about what may happen when standard pathways do not fully control idiopathic multicentric Castleman disease (iMCD), especially the TAFRO subtype. Across studies, outcomes looked mixed but understandable: some people stabilized or improved when treatment was changed or combined, and some people stayed well even after stopping treatment once inflammation tests had fully normalized. Because several findings come from very small studies or individual cases, they are best read as early clues about which approaches might be worth studying more, not as proof that one approach works for everyone. [1] [2] [3] [4]

For people with iMCD that did not respond to tocilizumab (an IL-6 blocker), an exploratory trial tested sirolimus (a drug that blocks a growth and inflammation signaling pathway) but enrolled only 2 patients before stopping early. The main score the trial aimed to improve did not improve during the blinded phase, yet the person on sirolimus appeared to have more stable disease and better quality-of-life measures than the person on placebo, and the person who switched from placebo to sirolimus later showed improvement on some measures. This keeps sirolimus on the research radar for IL-6-resistant iMCD, while also showing that stronger evidence is still needed. [1]

In iMCD-TAFRO, a multicenter retrospective study focused on what happened after people stopped therapy once their lab markers had reached a biochemical complete response. Most (85.2%) stayed in biochemical remission over a median of 31 months of follow-up, while 4 people progressed within about 5 to 12 months after stopping; those who progressed were successfully treated again using the same or similar approaches. This helps clarify that, at least in routine care, some patients can have longer-lasting control after reaching deep lab-based remission, but a smaller group may relapse and need treatment again. [2]

Several case reports described options used when TAFRO syndrome was relapsed or not responding to IL-6 inhibition alone. Two patients with relapsed or refractory TAFRO improved after ruxolitinib (a JAK-STAT pathway inhibitor), and one separate patient with IL-6-inhibitor-refractory iMCD-TAFRO had a complete and durable remission only after IL-1 blockade (anakinra) was added to ongoing IL-6 blockade (tocilizumab). Together, these cases point to the idea that more than one inflammatory pathway can be involved in some people, even when IL-6 is already being targeted. [3] [4]

For patients and caregivers, this theme mainly adds perspective about what researchers and clinicians are trying when iMCD or TAFRO does not follow an expected course. The strongest evidence in this set is the real-world discontinuation study, which suggests many people who reach full lab normalization can stay well for years, while a smaller portion may relapse and need treatment again. The medication-switch and combination-treatment findings (sirolimus, ruxolitinib, and combined IL-1 plus IL-6 blockade) are promising but still early, because they come from very small numbers of patients and need confirmation in larger studies. This information is most likely to matter in future research and in understanding possible paths when standard options are not enough, rather than changing anything immediately for most people. [1] [2] [3] [4]

This month made kidney involvement in Castleman disease feel more concrete and easier to picture: it was much more common in multicentric disease than unicentric disease, and when kidney tissue was examined, a small-vessel injury pattern was frequently seen. Importantly, the study also reported that kidney involvement did not clearly worsen overall survival in their cohort, which may help reduce the sense that kidney findings automatically mean a worse outlook. At the same time, the results came from one hospital system and many patients lacked long-term follow-up, so the exact risks for an individual person can still vary. [5]

In a retrospective cohort of 183 people, kidney involvement was reported in 55.22% of multicentric Castleman disease compared with 6.03% of unicentric disease. Among multicentric cases who had a kidney biopsy, thrombotic microangiopathy (a type of small blood vessel injury in the kidney) was the most common pattern described. This helps clarify that kidney problems in Castleman disease are not all the same, and that biopsy results may show specific patterns rather than a single uniform diagnosis. [5]

Within the subgroup of iMCD-TAFRO patients who had kidney involvement, the study compared treatment approaches used in routine care and reported higher complete kidney remission rates with regimens the authors described as myeloma-like than with lymphoma-like regimens. The same study also noted that unicentric Castleman patients with kidney involvement who underwent surgery largely achieved complete kidney remission. Because this was not a randomized comparison and treatments were chosen based on clinical decisions, it cannot show which approach is best, but it adds detail about how kidney recovery looked in real-world practice. [5]

For patients, the main value here is a clearer picture of how often kidney involvement was seen and what it looked like when tested: it appeared far more often in multicentric disease, and a small-vessel injury pattern was common on biopsy. The study also reported similar overall survival between people with and without kidney involvement in this cohort, which may be reassuring but should be interpreted cautiously because it reflects one center and incomplete follow-up for some patients. These findings may matter now for understanding what doctors may look for when kidney issues come up, and later if confirmed across more settings to better predict outcomes and responses. [5]

This month also brought a mix of individual patient stories and lab-based studies that add context around how varied Castleman-related conditions can be. The case reports collectively highlighted two recurring themes: diagnosis can be challenging when symptoms overlap with other immune diseases, and unusual locations or immune complications can occur even in unicentric disease. In parallel, two biology-focused studies pointed toward specific immune pathways and genetic or viral factors that may help explain why some people develop severe inflammation, but these are still research findings rather than tools used in everyday care. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16]

Several reports emphasized that Castleman disease can overlap in appearance with other immune-driven conditions, especially in the IgG4-related disease spectrum. One case described a person initially considered in a Castleman/IgG4 overlap, where biopsy supported IgG4-related disease and the patient achieved a long remission with rituximab-based treatment, while another case described a proposed "oligocentric" form where findings did not neatly fit unicentric or multicentric categories and responded to steroids and then rituximab. A larger retrospective series of cutaneous and systemic plasmacytosis also reported frequent lab abnormalities like elevated IgG4 and IL-6, with some patients later developing multicentric Castleman disease, reinforcing that these boundaries can be blurry over time. [11] [10] [16]

Multiple case reports reinforced that unicentric Castleman disease can show up in uncommon places and can sometimes link to immune complications. Three children with parotid-gland unicentric hyaline vascular disease had endoscopic-assisted surgery with uneventful recoveries and no recurrence during 6 to 18 months of follow-up, and a separate teen had a rare paravertebral unicentric lesion that was removed surgically with an uneventful recovery. Other single-patient reports described autoimmune complications occurring alongside unicentric disease, including paraneoplastic pemphigus with myasthenia gravis after a mediastinal mass, and paraneoplastic autoimmune multiorgan syndrome linked to a stroma-rich hyaline vascular lesion. [7] [9] [14] [8]

Two reports focused on virus-related or inflammatory signaling biology that could matter most for HHV-8/KSHV-associated disease and for severe inflammatory subtypes. A lab study isolated antibodies against a key KSHV surface complex and showed that several could block infection of certain cell types, mapping where they bind to guide future vaccine or therapy design. Separately, a genetics and immune-profiling study reported a high prevalence of MEFV gene variants in their Castleman cohort and linked variant carrier status to more severe disease, especially in TAFRO, along with signals of IL-6 pathway activation in certain immune cells. [12] [13]

Two additional case reports illustrated how broad the Castleman spectrum can be in real life. One HIV-positive patient with KSHV-associated multicentric Castleman disease required repeat lymph node biopsies before diagnosis and later had a long remission after a multi-drug approach that included ganciclovir and rituximab. Another patient with HHV-8-negative iMCD presented with Raynaud's phenomenon and had partial improvement with tocilizumab along with a drop in CRP (an inflammation blood test). [6] [15]

For patients and caregivers, these reports mainly add understanding of the range of ways Castleman disease and related immune conditions can appear, rather than providing generalizable expectations. The case reports show that tissue diagnosis and careful sorting between look-alike conditions (such as IgG4-related disease) can be important, and they give real examples of how treatment and recovery can vary across unicentric, multicentric, and virus-associated forms. The biology studies may matter later by supporting future vaccine or targeted-therapy research for KSHV and by suggesting that inherited immune gene variants could influence severity in some people, but neither finding is yet a standard part of routine care. What remains uncertain is how often these patterns apply across broader groups and how best to use them to predict an individual person’s course. [11] [10] [16] [7] [9] [14] [8] [12] [13] [6] [15]